AntiHIV, antibacterial and antifungal activities of some novel 2-methyl-3-(substituted methylamino)-(3H)-quinazolin-4-ones

Indian Journal of Pharmaceutical Sciences

Volumn 69, Issue 2, 2007, Pages 304-307

  Alagarsamy, V ^a   Murugesan, S ^a   Dhanabal, K ^a   Murugan, M ^a   De Clercq, E ^b  

^a ARULMIGU KALASALINGAM COLLEGE OF PHARMACY   (India)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (4 CARBOXYPHENYLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (4 SULFONAMIDOPHENYLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (BENZIMIDAZOL 1 YLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (DIETHYLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (DIMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (MORPHOLINYLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (PHENYLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (PIPERAZINYLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (PYRIDIN 2 YLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; 2 METHYL 3 (PYRROLIDINYLMETHYLAMINO) (3H) QUINAZOLIN 4 ONE; AGAR; AMINE; CLOTRIMAZOLE; FORMALDEHYDE; HYDROGEN; NORFLOXACIN; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; ATOM; BACTERIUM; CONTROLLED STUDY; DILUTION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PURITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FUNGUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 34347370890     PISSN: 0250474X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0250-474X.33167     Document Type: Article

References (10)

1. Papoulis, R., Andrew, T., Ronald, Q. and Sherry, F., J. Med. Chem., 1999, 42,1007
2. Shah, B.R., Bhatt, J.J., Patel, H.H., Undavia, N.H., Trivedi, P.B. and Desai, N. C., Indian J. Chem., 1995, 34B, 201
3. Jantova, S., Hudecova, D., Stankovsty, S. and Ruzotoval, H., Folia Microbial Prabha., 1995, 40, 611.
4. Chan, J.H., Hong, J.S., Kuper, L.F., Jeyner, S.S., Tansik, R.I. and Boytos, C.M., J. Med. Chem., 1995, 38, 3608.
5. Alagarsamy, V., Pathak, U.S., Sriram, D., Pandeya, S.N. and Clercq, E.De., Indian J. Pharm. Sci., 2000, 62, 433.
6. Alagarsamy, V., Pathak, U.S., Venkatesha Perumal, R., Meena, S., Thirumurugan, K., Rajasolomon, V. and Clercq E.De., Indian J. Pharm. Sci., 2003, 65, 293.
7. Alagarsamy, V., Revathi, R., Ramaseshu, K.V., Rajasekaran, S. and Clercq E.De., Indian J. Pharm. Sci., 2004, 66, 459.
8. Alagarsamy, V., Pharmazie., 2004, 59, 10.
9. Greenwood, D., Slack, R.C.B. and Peutherer, J.F., In; Medical microbiology 14 th Edn., ELBS, London,1992, 1.
10. Barry, A., Eds., In; antibiotics in Laboratory Medicines, 5 th Edn., William and Willkins, Baltimore, MD, 1991, 1